165 related articles for article (PubMed ID: 34767473)
41. Should serum calcitonin be routinely measured in patients presenting with thyroid nodule?
Tormey WP; Byrne B; Hill AD; Sherlock M; Thompson CJ
Minerva Endocrinol; 2017 Dec; 42(4):306-310. PubMed ID: 28092147
[TBL] [Abstract][Full Text] [Related]
42. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
43. Elevated calcitonin and procalcitonin levels in nonmedullary benign and malignant thyroid nodules.
Giovanella L; Maffioli M; Suriano S; Dorizzi RM
Clin Endocrinol (Oxf); 2010 Jun; 72(6):852-3. PubMed ID: 19863575
[No Abstract] [Full Text] [Related]
44. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease?
Costante G; Filetti S
Oncologist; 2011; 16(1):49-52. PubMed ID: 21212427
[TBL] [Abstract][Full Text] [Related]
45. Influence of chronic autoimmune thyroiditis and papillary thyroid cancer on serum calcitonin levels.
Rosario PW; Calsolari MR
Thyroid; 2013 Jun; 23(6):671-4. PubMed ID: 23327335
[TBL] [Abstract][Full Text] [Related]
46. Basal and stimulated calcitonin for the diagnosis of medullary thyroid cancer: updated thresholds and safety assessment.
Fugazzola L; Di Stefano M; Censi S; Repaci A; Colombo C; Grimaldi F; Magri F; Pagotto U; Iacobone M; Persani L; Mian C
J Endocrinol Invest; 2021 Mar; 44(3):587-597. PubMed ID: 32656666
[TBL] [Abstract][Full Text] [Related]
47. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma.
Barbot N; Calmettes C; Schuffenecker I; Saint-André JP; Franc B; Rohmer V; Jallet P; Bigorgne JC
J Clin Endocrinol Metab; 1994 Jan; 78(1):114-20. PubMed ID: 7904611
[TBL] [Abstract][Full Text] [Related]
48. Elevated basal calcitonin levels in a patient with a hurthle-cell carcinoma of the thyroid and neuroendocrine differentiation: report of a case.
Munitiz V; Martinez-Barba E; Riquelme J; Rodriguez JM; Piñero A; Parrilla P
Surg Today; 2005; 35(5):404-6. PubMed ID: 15864423
[TBL] [Abstract][Full Text] [Related]
49. Calcitonin levels by ECLIA correlate well with RIA values in higher range but are affected by sex, TgAb, and renal function in lower range.
Ito Y; Kaneko H; Sasaki Y; Ohana N; Ichijo M; Furuya F; Suzuki S; Suzuki S; Shimura H
Endocr J; 2020 Jul; 67(7):759-770. PubMed ID: 32269183
[TBL] [Abstract][Full Text] [Related]
50. Diagnosis, treatment, and follow-up of medullary thyroid carcinoma: recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism.
Maia AL; Siqueira DR; Kulcsar MA; Tincani AJ; Mazeto GM; Maciel LM
Arq Bras Endocrinol Metabol; 2014 Oct; 58(7):667-700. PubMed ID: 25372577
[TBL] [Abstract][Full Text] [Related]
51. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada.
Daniels GH
Thyroid; 2011 Nov; 21(11):1199-207. PubMed ID: 21936671
[TBL] [Abstract][Full Text] [Related]
52. Fine-Needle Aspiration with Immunohistochemistry Using a Modified Scrape Cell Block Technique for the Diagnosis of Thyroid and Parathyroid Nodules.
Wuertz FG; Kresnik E; Malle P; Hyden M; Lind P; Rogatsch H; Gallowitsch HJ
Acta Cytol; 2016; 60(2):118-30. PubMed ID: 27231232
[TBL] [Abstract][Full Text] [Related]
53. [Ultrasonographic features of thyroid carcinoma of different sizes: comparison between medullary thyroid carcinomas and papillary thyroid carcinomas].
Zhang D; Yang F; Wang Y; Mu JL; Wei XQ; Wei X
Zhonghua Zhong Liu Za Zhi; 2024 Feb; 46(2):133-139. PubMed ID: 38418187
[No Abstract] [Full Text] [Related]
54. Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer.
Allelein S; Ehlers M; Morneau C; Schwartz K; Goretzki PE; Seppel T; Feldkamp J; Krieg A; Knoefel WT; Kuebart A; Haase M; Dringenberg T; Schmid C; Schott M
Horm Metab Res; 2018 Jan; 50(1):23-28. PubMed ID: 29169190
[TBL] [Abstract][Full Text] [Related]
55. Usefulness of preoperative serum calcitonin in patients with nodular thyroid disease without suspicious history or cytology for medullary thyroid carcinoma.
Rosário PW; Penna GC; Brandão K; Souza BÉ
Arq Bras Endocrinol Metabol; 2013 Jun; 57(4):312-6. PubMed ID: 23828436
[TBL] [Abstract][Full Text] [Related]
56. A Genomic Alternative to Identify Medullary Thyroid Cancer Preoperatively in Thyroid Nodules with Indeterminate Cytology.
Kloos RT; Monroe RJ; Traweek ST; Lanman RB; Kennedy GC
Thyroid; 2016 Jun; 26(6):785-93. PubMed ID: 26992356
[TBL] [Abstract][Full Text] [Related]
57. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
[TBL] [Abstract][Full Text] [Related]
58. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
[TBL] [Abstract][Full Text] [Related]
59. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease.
Rink T; Truong PN; Schroth HJ; Diener J; Zimny M; Grünwald F
Thyroid; 2009 Apr; 19(4):327-32. PubMed ID: 19355822
[TBL] [Abstract][Full Text] [Related]
60. [Total thyroidectomy in C-cell hyperplasia of the thyroid gland].
Stojanović D; Paunović I; Caparević Z; Lalosević D; Stojanović M
Med Pregl; 2003; 56(9-10):481-4. PubMed ID: 14740541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
